# A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients

> **NCT03047837** · PHASE2 · TERMINATED · sponsor: **Ente Ospedaliero Ospedali Galliera** · enrollment: 160 (actual)

## Conditions studied

- Tertiary Prevention in Colon Cancer

## Interventions

- **DRUG:** ASA
- **DRUG:** MET
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03047837
- **Lead sponsor:** Ente Ospedaliero Ospedali Galliera
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-15
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 160 (ACTUAL)
- **Why stopped:** lack of enrolment
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03047837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03047837, "A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03047837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*